All In Biotech

Drug Trial Radar · NCT00921375

Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia

Last checked: Nov 20, 2026Latest source record: Dec 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Feb 2010

Primary completion

Dec 2011

Study completion Jan 2012

Sponsor

Lead sponsor
Virchow GroupIndustry
Sponsor type
Industry
First posted
Jun 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 1 year, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, open-label, multicentre study. Hundred eligible patients with stage III or IV non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL) with a peripheral white blood cell (WBC) count of \> 25,000/µL or any leukemia or lymphoma with plasma uric acid level of at least 8 mg/dL will be treated with rasburicase 0.20 mg/kg body weight intravenously for 4 days. The primary endpoints viz., the percentage of reduction in plasma uric acid at 4 hrs after uric acid-lowering therapy, plasma uric acid AUC 0-96 hr and incidence of adverse events will be assessed during 11 days study period.

Conditions

  • Hyperuricemia

Interventions

  • TULYDrug

    TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of reduction in plasma uric acid at 4 hrs after uric acid-lowering therapyTime frame: At the end of 4 hrs after initiation of uric acid lowering therapy; during 96 hrs of uric acid lowering therapy; Adverse events during the entire study period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Raghunathrao

    Hyd, Andhra Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.